Pancreatic Cancer Subtypes Unveiled by BPGbio at ASCO GI 2025 for Tailored Treatment BPGbio, Inc., a clinical-stage biopharma company specializing in mitochondrial biology and protein homeostasis, today revealed new findings…
DNA Nanobots Appoints Dr. John C. Byrd to Scientific Advisory Board DNA Nanobots, a leader in biotechnology specializing in DNA nanoparticles for targeted therapeutics, has announced the addition of Dr.…
Glox Therapeutics Wins £3M Cystic Fibrosis Funding Glox Therapeutics, a leader in developing precision antibiotic therapies using naturally occurring bacteriocins, has announced it has been awarded a portion of the…
Agreement Between InnoCare, KeyMed, and Prolium for CD20xCD3 Bispecific Antibody License InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) have announced the signing of an exclusive license…
ImmunoPrecise Antibodies Realigns Pipeline with AI and First-Principles Innovation ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today unveiled its AI-powered pipeline, designed to revolutionize therapeutic development. This new system combines cutting-edge artificial…
Atara Biotherapeutics Provides Update on EBVALLO™ (tabelecleucel) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, recently received a Complete Response Letter (CRL) from the U.S. Food and Drug…
Inflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy Inflammasome Therapeutics, a clinical-stage biotech company at the forefront of developing dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative…
Neurodegenerative Disease Imaging and Biomarkers: Enigma and UW-Madison Partner Enigma Biomedical USA, Inc. (Enigma) and the University of Wisconsin–Madison (UW–Madison) have announced a new partnership aimed at advancing the development…
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, presented an exciting update to the investment community during the 43rd annual J.P. Morgan Healthcare Conference. In addition to…
Alnylam Reports Q4 and Full Year 2024 Revenue and 2025 Guidance Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, today announced preliminary global net product revenues…
Gilead and LEO Pharma Partner on Oral STAT6 Program Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today revealed a strategic partnership aimed at fast-tracking the development and commercialization of…
Compass Pathways Sets Price for Underwritten Offering Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on accelerating access to evidence-based mental health innovations, has announced the pricing of an…